Elobixibat Hydrate

N/A

Report date: 2022/09/05 20:00:48
NMEFirst In Class

Base Information

Drug NameElobixibat Hydrate
Drug Alias Name依洛昔巴特ElobixibatElobixibatum依洛昔巴Goofice +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIleal bile acid transporter inhibitors
TargetsIleal bile acid transporter
Therapy Area/IndicationsConstipationDyslipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsConstipation
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2018/01/19
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca PlcEa PharmaAlbireo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesEa PharmaSynmosa Biopharma Corp
Inactive CompaniesAlbireo Pharma IncFerring BvNational Center For Research Resources
Active IndicationsConstipation
Inactive IndicationsDyslipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeA06AX
Related LinksWikipediaKEGG